Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.61 |
| ▸ | AR | P10275 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.60 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9819236 | 1.00 | MAOB (0.61) | MAOBADORA3ARKDM4ECYP19A1 | |
| SCHEMBL15147107 | 1.00 | MAOB (0.61) | MAOBADORA3ARKDM4ECYP19A1 | |
| Dimethylamine SCHEMBL11174999 | 0.95 | MAOB (0.56) | MAOBADORA3ARKDM4ECYP19A1 | |
| SCHEMBL9384746 | 0.81 | MAOB (0.49) | MAOBADORA3ARKDM4ECYP19A1 | |
| SCHEMBL8373024 | 0.78 | MAOB (0.62) | MAOBADORA3ARKDM4ECYP19A1 | |
| SCHEMBL10344116 | 0.78 | MAOB (0.62) | MAOBADORA3ARKDM4ECYP19A1 | |
| SCHEMBL24969554 | 0.77 | MAOB (0.61) | MAOBADORA3ARKDM4ECYP19A1 | |
| SCHEMBL30274254 | 0.77 | MAOB (0.61) | MAOBADORA3ARKDM4ECYP19A1 | |
| SCHEMBL8043472 | 0.77 | MAOB (0.61) | MAOBADORA3ARKDM4ECYP19A1 | |
| SCHEMBL8185206 | 0.77 | MAOB (0.61) | MAOBADORA3ARKDM4ECYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1997028157-A1 | NOVEL PIPERIDINE DERIVATIVES 4-SUBSTITUTED BY AN IMIDAZOLIDIN-2-ON-1-YL-ETHYL, TETRAHYDROPYRIMIDIN-2-ON-1-YL-ETHYL AND 1,3-DIAZEPIN-2-ON-1-YL-ETHYL GROUP, AND USE THEREOF AS α2-ADRENERGIC RECEPTOR ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 1997-08-07 | — | — | WO | claimed |
| US-20240182436-A1 | SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| CN-113185484-B | Chromone compound and preparation method and application thereof | 江西中医药大学 | 2023-05-02 | — | — | CN | disclosed |
| WO-2022217248-A1 | SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| CN-114853707-A | Method for synthesizing difluoro-hydrogen methylated 2, 3-dihydrobenzopyran-4-ketone derivative | 上饶师范学院 | 2022-08-05 | — | — | CN | disclosed |
| US-20200347043-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-05 | — | — | US | disclosed |
| WO-2020223536-A1 | SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2020-11-05 | — | — | WO | disclosed |
| CN-110114343-A | Pyrazolopyrimidine compound and its application method | 豪夫迈·罗氏有限公司 | 2019-08-09 | — | — | CN | disclosed |
| CN-109293493-A | With the inhibition active novel benzhydryl class compound of mycobacterium tuberculosis | 清华大学 | 2019-02-01 | — | — | CN | disclosed |
| US-20180037587-A1 | Substituted Tricyclics and Method of Use | ABBVIE S.Á.R.L. (LU) | 2018-02-08 | — | — | US | disclosed |
| EP-1124814-B1 | AROMATIC DERIVATIVES AND IRON COMPLEXES THEREOF FOR THE USE AS NORMALISING AGENTS OF THE IRON LEVEL | MEDIDOM LAB (CH) | 2002-12-18 | — | — | EP | disclosed |
| US-6455578-B1 | IRON CHELATING AGENTS FOR TREATMENT OF IRON OVERLOAD AND ANEMIA. | LABORATOIRE MEDIDOM S.A. (CH) | 2002-09-24 | — | — | US | disclosed |
| EP-1124814-A1 | AROMATIC DERIVATIVES AND IRON COMPLEXES THEREOF FOR THE USE AS NORMALISING AGENTS OF THE IRON LEVEL | LABORATOIRE MEDIDOM S.A. (CH) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026205-A1 | AROMATIC DERIVATIVES AND IRON COMPLEXES THEREOF FOR THE USE AS NORMALISING AGENTS OF THE IRON LEVEL | LABORATOIRE MEDIDOM S.A. (CH) | 2000-05-11 | — | — | WO | disclosed |
| WO-1997028157-A1 | NOVEL PIPERIDINE DERIVATIVES 4-SUBSTITUTED BY AN IMIDAZOLIDIN-2-ON-1-YL-ETHYL, TETRAHYDROPYRIMIDIN-2-ON-1-YL-ETHYL AND 1,3-DIAZEPIN-2-ON-1-YL-ETHYL GROUP, AND USE THEREOF AS α2-ADRENERGIC RECEPTOR ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 1997-08-07 | — | — | WO | disclosed |
| CN-1015545-B | preparation method of glycolic acid derivative for treating diabetic complications | PFIZER (US) | 1992-02-19 | — | — | CN | disclosed |
| EP-0230379-B1 | CHROMAN- AND THIOCHROMAN-4-ACETIC ACIDS USEFUL IN THE TREATMENT OF DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1991-04-03 | — | — | EP | disclosed |
| US-4853410-A | Hydroxyacetic acid derivatives for the treatment of diabetic complications | PFIZER INC. (US) | 1989-08-01 | — | — | US | disclosed |
| CN-87100191-A | The hydroxy acid derivative of treatment diabetic complication | — | 1987-09-09 | — | — | CN | disclosed |
| US-4261988-A | ANTICHOLESTEROL AGENTS USED IN ANIMAL HUSBANDRY | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347043-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | MAOB 3069/4885ADORA3 4386/4885AR 2929/4885 |
| US-20180037587-A1 | Substituted Tricyclics and Method of Use | CFTR, F12, CHRM2 | MAOB 2157/4885ADORA3 868/4885AR 3532/4885 |
| US-20240182436-A1 | SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ARSA, SNCA, F12 | MAOB 186/4885ADORA3 444/4885AR 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.